# üìã Entity Types Reference

This document describes all 13 entity types that the W2NER Clinical NER model can identify.

---

## 1. DRUG

**Description:** Medications, pharmaceuticals, and active substances

**Examples:**
- –¶–∏—Ç–∞—Ä–∞–±–∏–Ω (Cytarabine)
- –ú–µ—Ç–æ—Ç—Ä–µ–∫—Å–∞—Ç (Methotrexate)
- –î–∞–∑–∞—Ç–∏–Ω–∏–± (Dasatinib)
- –ë–ª–∏–Ω–∞—Ç—É–º–æ–º–∞–± (Blinatumomab)
- –†–∏—Ç—É–∫—Å–∏–º–∞–± (Rituximab)

**Patterns:**
- Generic drug names
- Brand names
- Active ingredients
- Drug combinations

---

## 2. ACTION / INTERVENTION

**Description:** Medical actions, procedures, and interventions

**Examples:**
- –†–µ–∫–æ–º–µ–Ω–¥—É–µ—Ç—Å—è (Recommended)
- –ù–∞–∑–Ω–∞—á–∏—Ç—å (Prescribe)
- –ü—Ä–æ–≤–µ—Å—Ç–∏ (Conduct)
- –í—ã–ø–æ–ª–Ω–∏—Ç—å (Perform)
- –û—Ü–µ–Ω–∏—Ç—å (Assess)

**Patterns:**
- Imperative verbs
- Recommendations
- Clinical actions
- Treatment steps

---

## 3. ADVERSE_EVENT / WARNING

**Description:** Side effects, adverse events, and warnings

**Examples:**
- –¢–æ–∫—Å–∏—á–Ω–æ—Å—Ç—å (Toxicity)
- –ù–µ–π—Ç—Ä–æ–ø–µ–Ω–∏—è (Neutropenia)
- –¢–æ—à–Ω–æ—Ç–∞ (Nausea)
- –ê–ª–ª–µ—Ä–≥–∏—á–µ—Å–∫–∞—è —Ä–µ–∞–∫—Ü–∏—è (Allergic reaction)

**Patterns:**
- Side effects
- Complications
- Risks
- Warnings

---

## 4. DOSAGE

**Description:** Drug dosages and concentrations

**Examples:**
- 100 –º–≥/–º¬≤ (100 mg/m¬≤)
- 500 –º–≥ per os (500 mg orally)
- 2 –º–≥/–∫–≥ (2 mg/kg)

**Patterns:**
- Number + unit
- Concentration expressions
- Dose calculations

---

## 5. üß™ PROCEDURE / TEST

**Description:** Diagnostic and therapeutic procedures

**Examples:**
- –ö–¢ (CT scan)
- –ú–†–¢ (MRI)
- –£–ó–ò (Ultrasound)
- –ü–≠–¢ (PET scan)
- –ë–∏–æ–ø—Å–∏—è (Biopsy)

**Patterns:**
- Imaging procedures
- Laboratory tests
- Diagnostic methods
- Therapeutic procedures

---

## 6. AGE_GROUP / POPULATION

**Description:** Patient populations and age groups

**Examples:**
- –î–µ—Ç–∏ (Children)
- –í–∑—Ä–æ—Å–ª—ã–µ (Adults)
- –ë–µ—Ä–µ–º–µ–Ω–Ω—ã–µ (Pregnant women)
- –ü–∞—Ü–∏–µ–Ω—Ç—ã —Å—Ç–∞—Ä—à–µ 65 –ª–µ—Ç (Patients over 65)

**Patterns:**
- Age ranges
- Special populations
- Gender-specific groups
- Demographic categories

---

## 7. FOLLOW_UP

**Description:** Follow-up schedules and monitoring

**Examples:**
- –ù–∞–±–ª—é–¥–µ–Ω–∏–µ (Follow-up)
- –ö–æ–Ω—Ç—Ä–æ–ª—å (Monitoring)
- –î–∏–Ω–∞–º–∏—á–µ—Å–∫–æ–µ –Ω–∞–±–ª—é–¥–µ–Ω–∏–µ (Dynamic monitoring)

**Patterns:**
- Monitoring schedules
- Follow-up visits
- Surveillance plans

---

## 8. TIME_WINDOW

**Description:** Time frames and temporal expressions

**Examples:**
- –ö–∞–∂–¥—ã–µ 3 –º–µ—Å—è—Ü–∞ (Every 3 months)
- –í —Ç–µ—á–µ–Ω–∏–µ 2 –Ω–µ–¥–µ–ª—å (Within 2 weeks)
- –ï–∂–µ–¥–Ω–µ–≤–Ω–æ (Daily)

**Patterns:**
- Duration expressions
- Frequency markers
- Time intervals

---

## 9. LAB_VALUE / MEASUREMENT

**Description:** Laboratory values and clinical measurements

**Examples:**
- –£—Ä–æ–≤–µ–Ω—å –≥–µ–º–æ–≥–ª–æ–±–∏–Ω–∞ (Hemoglobin level)
- –ö—Ä–µ–∞—Ç–∏–Ω–∏–Ω (Creatinine)
- –õ–µ–π–∫–æ—Ü–∏—Ç—ã (Leukocytes)

**Patterns:**
- Lab parameters
- Vital signs
- Clinical measurements
- Reference ranges

---

## 10. SEVERITY/STAGE

**Description:** Disease severity and staging

**Examples:**
- –°—Ç–∞–¥–∏—è II (Stage II)
- –í—ã—Å–æ–∫–∏–π —Ä–∏—Å–∫ (High risk)
- –¢—è–∂–µ–ª–∞—è —Ñ–æ—Ä–º–∞ (Severe form)

**Patterns:**
- Cancer stages
- Risk categories
- Severity levels

---

## 11. CONTRAINDICATION

**Description:** Contraindications and restrictions

**Examples:**
- –ù–µ —Ä–µ–∫–æ–º–µ–Ω–¥—É–µ—Ç—Å—è (Not recommended)
- –ü—Ä–æ—Ç–∏–≤–æ–ø–æ–∫–∞–∑–∞–Ω–æ (Contraindicated)
- –ó–∞–ø—Ä–µ—â–µ–Ω–æ (Prohibited)

**Patterns:**
- Absolute contraindications
- Relative contraindications
- Restrictions

---

## 12. DURATION

**Description:** Treatment duration

**Examples:**
- 6 –º–µ—Å—è—Ü–µ–≤ —Ç–µ—Ä–∞–ø–∏–∏ (6 months of therapy)
- –ö—É—Ä—Å 21 –¥–µ–Ω—å (21-day course)

**Patterns:**
- Treatment lengths
- Cycle durations
- Therapy periods

---

## 13. FREQUENCY

**Description:** Treatment frequency

**Examples:**
- 2 —Ä–∞–∑–∞ –≤ –¥–µ–Ω—å (Twice daily)
- –ö–∞–∂–¥—ã–µ 4 —á–∞—Å–∞ (Every 4 hours)
- –û–¥–Ω–æ–∫—Ä–∞—Ç–Ω–æ (Once)

**Patterns:**
- Dosing frequency
- Administration schedules
- Repetition patterns

---

## Entity Type Distribution (Test Data)

| Entity Type | Count | Percentage |
|------------|-------|------------|
| ACTION / INTERVENTION | 939 | 40.5% |
| ADVERSE_EVENT / WARNING | 688 | 29.7% |
| DRUG | 294 | 12.7% |
| AGE_GROUP / POPULATION | 212 | 9.2% |
| FOLLOW_UP | 122 | 5.3% |
| PROCEDURE / TEST | 28 | 1.2% |
| TIME_WINDOW | 25 | 1.1% |
| LAB_VALUE / MEASUREMENT | 7 | 0.3% |
| SEVERITY/STAGE | 1 | 0.0% |
| CONTRAINDICATION | 2 | 0.1% |
| DOSAGE | 5 | 0.2% |
| DURATION | - | - |
| FREQUENCY | - | - |

---

## Notes

- Some entity types are more common than others in clinical guidelines
- Distribution varies by document type and medical specialty
- Model may require fine-tuning for specific domains
